<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83844">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013791</url>
  </required_header>
  <id_info>
    <org_study_id>192371-024</org_study_id>
    <nct_id>NCT02013791</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in
      patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be
      studied in Stage 2 based on results from Stage 1. No patients participating in Stage 1 will
      participate in Stage 2 of this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal Staining Score Using a 6-Point Scale</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vehicle administered to study eye and Sham administered to non-study eye on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation Dose A administered to study eye and Vehicle administered to non-study eye on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation Dose B administered to study eye and Vehicle administered to non-study eye on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation (dose to be determined from Stage 1) administered to study eye and Sham administered to non-study eye on Day 1. Both eyes (study eye and non-study eye) will be treated with Cyclosporine New Ophthalmic Formulation beginning at Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation (dose to be determined from Stage 1) administered to study eye and Sham administered to non-study eye on Day 1. Both eyes (study eye and non-study eye) will be treated with Cyclosporine New Ophthalmic Formulation beginning at Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation (dose to be determined from Stage 1) administered to study eye and Sham administered to non-study eye on Day 1. Both eyes (study eye and non-study eye) will be treated with Cyclosporine New Ophthalmic Formulation beginning at Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation Dose D administered to study eye and Vehicle administered to non-study eye on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation Dose E administered to study eye and Vehicle administered to non-study eye on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation Dose G administered to study eye and Vehicle administered to non-study eye on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine New Ophthalmic Formulation Dose H administered to study eye and Vehicle administered to non-study eye on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle of cyclosporine administered as per protocol on Day 1</description>
    <arm_group_label>Stage 1 Cohort 1</arm_group_label>
    <arm_group_label>Stage 1 Cohort 2</arm_group_label>
    <arm_group_label>Stage 1 Cohort 3</arm_group_label>
    <arm_group_label>Stage 1 Cohort 4</arm_group_label>
    <arm_group_label>Stage 1 Cohort 5</arm_group_label>
    <arm_group_label>Stage 1 Cohort 6</arm_group_label>
    <arm_group_label>Stage 1 Cohort 7</arm_group_label>
    <arm_group_label>Stage 1 Cohort 8</arm_group_label>
    <arm_group_label>Stage 1 Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham administered to non-study eye as per protocol on Day 1</description>
    <arm_group_label>Stage 1 Cohort 1</arm_group_label>
    <arm_group_label>Stage 2 Group 1</arm_group_label>
    <arm_group_label>Stage 2 Group 2</arm_group_label>
    <arm_group_label>Stage 2 Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine New Ophthalmic Formulation</intervention_name>
    <description>Cyclosporine New Ophthalmic Formulation administered as per protocol</description>
    <arm_group_label>Stage 1 Cohort 2</arm_group_label>
    <arm_group_label>Stage 1 Cohort 3</arm_group_label>
    <arm_group_label>Stage 1 Cohort 4</arm_group_label>
    <arm_group_label>Stage 2 Group 1</arm_group_label>
    <arm_group_label>Stage 2 Group 2</arm_group_label>
    <arm_group_label>Stage 2 Group 3</arm_group_label>
    <arm_group_label>Stage 1 Cohort 5</arm_group_label>
    <arm_group_label>Stage 1 Cohort 6</arm_group_label>
    <arm_group_label>Stage 1 Cohort 7</arm_group_label>
    <arm_group_label>Stage 1 Cohort 8</arm_group_label>
    <arm_group_label>Stage 1 Cohort 9</arm_group_label>
    <other_name>Restasis® X</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe dry eye disease in both eyes

          -  Best-corrected visual acuity (BCVA) of 20/100 or better in each eye

        Exclusion Criteria:

          -  Use of any cyclosporine preparations within 3 months

          -  Use of topical medications, other than artificial tears, in the eyes within 1 month

          -  Use of contact lenses in either eye within 1 month

          -  Stage 2 only: Participation in Stage 1 of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>1-800-347-4500</phone>
    <email>IR-CTRegistration@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sall Research Medical Center</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lugene Eye Institute</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lakeside Vision Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Nanduri's Associated Eye Surgeons Medical Group/Envision Eye</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>M.D. Med Associates</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wolstan &amp; Goldberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vision Institute</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University - Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abrams Eye Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Eye Centers of Racine and Kenosha</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 26, 2017</lastchanged_date>
  <firstreceived_date>December 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
